Table 3.
Adverse events during active follow‐up
| Patients with adverse events, n (%) | Active follow‐up n = 34 | Adverse event status a |
|---|---|---|
| Anemia | 3 (9) | Ongoing b |
| Arthralgia | 2 (6) | 1 ongoing; 1 new |
| Bone pain | 2 (6) | 1 ongoing; 1 new |
| Humerus fracture | 1 (3) | New |
| Muscular weakness | 1 (3) | New |
| Musculoskeletal pain | 1 (3) | New c |
| Osteonecrosis of jaw | 1 (3) | Ongoing |
| Paresthesia | 1 (3) | Ongoing |
| Spinal cord compression | 1 (3) | New |
| Spinal pain | 2 (6) | 1 ongoing; 1 new |
a
Adverse event status is given relative to the treatment period: “ongoing” indicates events that began during the treatment period and continued in the active follow‐up; “new” indicates events that were new during active follow‐up.
b
All worsening of an existing event that started during the treatment period.
c
Patient had other events of musculoskeletal pain during the treatment period but at different body locations.